Log in

OTCMKTS:ONCYF - Oncolytics Biotech Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.74
+0.74 (+∞)
(As of 05/24/2018)
Today's Range
$0.74
Now: $0.74
$0.82
50-Day Range N/A
52-Week Range
$0.32
Now: $0.74
$0.90
Volume442,324 shs
Average Volume443,150 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ONCYF
Previous SymbolNASDAQ:ONCY
CUSIPN/A
CIKN/A
Phone403-670-7377

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive ONCYF News and Ratings via Email

Sign-up to receive the latest news and ratings for ONCYF and its competitors with MarketBeat's FREE daily newsletter.


Oncolytics Biotech (OTCMKTS:ONCYF) Frequently Asked Questions

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (OTCMKTS:ONCYF) announced its quarterly earnings results on Thursday, August, 6th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. View Oncolytics Biotech's earnings history.

Has Oncolytics Biotech been receiving favorable news coverage?

Media headlines about ONCYF stock have been trending somewhat negative on Tuesday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Oncolytics Biotech earned a news impact score of -1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutOncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the following people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 51)
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Daniel Douglas Von Hoff M.D., F.A.C.P., Consultant (Age 70)

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the OTCMKTS under the ticker symbol "ONCYF."

What is Oncolytics Biotech's stock price today?

One share of ONCYF stock can currently be purchased for approximately $0.74.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent NW Suite 210, Calgary A0, T2N 1X7. The company can be reached via phone at 403-670-7377 or via email at [email protected]


MarketBeat Community Rating for Oncolytics Biotech (OTCMKTS ONCYF)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  239
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONCYF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCYF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel